Perrigo Company plc

PRGO

IE00BGH1M568

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
31.94 ^USD	+2.14%		+3.70%	-0.75%

Apr. 25	Sector Update: Health Care Stocks Decline Late Afternoon	MT
Apr. 25	Perrigo Receives Binding Offer to Sell HRA Pharma Rare Diseases Business for Up to $295 Million	MT

Perrigo Company plc Announces the Relaunch of the AB Rated Generic Version of Transderm Scop 1.5 Mg

October 03, 2019 at 08:00 am EDT

Perrigo Company plc announced the relaunch of the AB rated generic equivalent of Transderm Scop (scopolamine 1.5 mg). Annual market sales of Transderm Scop and therapeutic equivalents for the 12 months ending August 2019 were approximately $147 million.

Latest news about Perrigo Company plc

Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Perrigo Receives Binding Offer to Sell HRA Pharma Rare Diseases Business for Up to $295 Million	Apr. 25	MT
Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc for approximately ?280 million.	Apr. 24	CI
Piper Sandler Raises Perrigo's Price Target to $39 From $35, Maintains Overweight Rating	Apr. 08	MT
CVS Caremark to cover Perrigo's birth control pill in US at zero cost for plan sponsors	Apr. 04	RE
Multiple CVS Caremark Plans to Cover Perrigo's Opill at No Cost	Apr. 04	MT
Multiple CVS Caremark Plans Reportedly to Cover Perrigo's Opill at No Cost	Apr. 04	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 19	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	Mar. 19	MT
Perrigo Shares Rise After Wisconsin Governor Makes Birth Control Pill Free for Medicaid Members	Mar. 19	MT
Transcript : Perrigo Company plc Presents at UBS Global Consumer and Retail Conference 2024, Mar-13-2024 04:00 PM	Mar. 13
Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors	Mar. 06	CI
Perrigo Company plc Commences Shipments of Opill to Retailers Nationwide, Empowering Millions to Enter A New Era of Reproductive Health Access in the United States	Mar. 04	CI
Perrigo Co Insider Bought Shares Worth $252,168, According to a Recent SEC Filing	Feb. 29	MT
JPMorgan Cuts Price Target on Perrigo to $41 From $48, Maintains Overweight Rating	Feb. 28	MT
Perrigo Company plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Sector Update: Health Care Stocks Mixed Premarket Tuesday	Feb. 27	MT
Sector Update: Health Care	Feb. 27	MT
Transcript : Perrigo Company plc, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Perrigo Q4 Adjusted Earnings Increase, Net Sales Flat	Feb. 27	MT
Earnings Flash (PRGO) PERRIGO COMPANY Reports Q4 Revenue $1.16B, vs. Street Est of $1.17B	Feb. 27	MT
Earnings Flash (PRGO) PERRIGO COMPANY Posts Q4 EPS $0.86, vs. Street Est of $0.83	Feb. 27	MT
Perrigo Company plc Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Perrigo Company plc Reports Earnings Guidance for the Fiscal Year 2024	Feb. 27	CI
Perrigo Company plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI

Chart Perrigo Company plc

Duration

Period

More charts

Company Profile

Perrigo Company plc is an Ireland-based provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. The Company's segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises its consumer self-care business (OTC, infant formula, and oral care categories, and contract manufacturing) in the United States and Canada, including the HRA Pharma self-care business (Women's Health and Skin-Care categories) in the United States and Canada. The CSCI segment comprises its consumer self-care business in Europe and Australia, which are primarily branded, its store brand business in the United Kingdom and parts of Europe and Asia and includes the HRA Pharma self-care business (Women's Health, Skin-Care and Rare-Disease categories) in Europe. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, Nutrition and others.

Sector

Pharmaceuticals

Calendar

2024-05-02 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Perrigo Company plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.94 USD

Average target price

39.72 USD

Spread / Average Target

+24.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PERRIGO COMPANY PLC	-0.75%	4.33B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals